[1]
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
[2]
Ferro A, Peleteiro B, Malvezzi M, et al. Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype. Eur J Cancer 2014; 50: 1330-44.
[3]
Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst 2008; 100: 1184-7.
[4]
Compare D, Rocco A, Nardone G. Risk factors in gastric cancer. Eur Rev Med Pharmacol Sci 2010; 14: 302-8.
[5]
Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-97.
[6]
Mikami J, Kimura Y, Makari Y, et al. Clinical outcomes and prognostic factors for gastric cancer patients with bone metastasis. World J Surg Oncol 2017; 15: 8.
[7]
Silvestris N, Pantano F, Ibrahim T, et al. Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey. PLoS One 2013; 8: e74402.
[8]
Riihimaki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. Metastatic spread in patients with gastric cancer. Oncotarget 2016; 7: 52307-16.
[9]
Shimazu K, Fukuda K, Yoshida T, Inoue M, Shibata H. High circulating tumor cell concentrations in a specific subtype of gastric cancer with diffuse bone metastasis at diagnosis. World J Gastroenterol 2016; 22: 6083-8.
[10]
Lee HJ, Nam KT, Park HS, et al. Gene expression profiling of metaplastic lineages identifies CDH17 as a prognostic marker in early stage gastric cancer. Gastroenterology 2010; 139: 213-25.
[11]
Marimuthu A, Jacob HK, Jakharia A, et al. Gene Expression Profiling of Gastric Cancer. J Proteomics Bioinform 2011; 4: 74-82.
[12]
Nam S, Lee J, Goh SH, et al. Differential gene expression pattern in early gastric cancer by an integrative systematic approach. Int J Oncol 2012; 41: 1675-82.
[13]
Zhang Q, Wang H, Ma Y, et al. Overexpression of Nedd9 is a prognostic marker of human gastric cancer. Med Oncol 2014; 31: 33.
[14]
Wu HQ, Wang HY, Sun XW, Liu F, Zhang LW, Tian FJ. Transcriptome profiling of cancers tissue in Chinese gastric patients by high-through sequencing. Int J Clin Exp Pathol 2016; 9: 3537-46.
[15]
Xiao J, Xia SY, Xia J, Xia Q, Wang XR. Transcriptome profiling of biliary atresia from new born infants by deep sequencing. Mol Biol Rep 2014; 12: 8063-9.
[16]
Xie L, Yang ZZ, Li GQ, et al. Genome-Wide Identification of Bone Metastasis-Related MicroRNAs in Lung Adenocarcinoma by High-Throughput Sequencing. PLoS One 2013; 8: e61212.
[17]
Cox MP, Peterson DA, Biggs PJ, Solexa QA. At-a-glance quality assessment of Illumina second-generation sequencing data. BMC Bioinformatics 2010; 11: 485.
[18]
Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 2009; 25: 1105-11.
[19]
Langmead B. Aligning short sequencing reads with Bowtie. Curr Protoc Bioinformatics 2010; 32: 1-14.
[20]
Trapnell C, Roberts A, Goff L, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc 2012; 7: 562-78.
[21]
Trapnell C, Williams BA, Pertea G, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 2010; 28: 511-5.
[22]
Blake JA, Dolan M, Drabkin H, et al. Gene Ontology annotations and resources. Nucleic Acids Res 2013; 41: D530-5.
[23]
Kanehisa M, Araki M, Goto S, et al. KEGG for linking genomes to life and the environment. Nucleic Acids Res 2008; 36: D480-4.
[24]
Huangda W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44-57.
[25]
Lopez R, Garrido E, Vazquez G, et al. A subgroup of HOX Abd-B gene is differentially expressed in cervical cancer. Int J Gynecol Cancer 2006; 16: 1289-96.
[26]
Hur H, Lee JY, Yang S, Kim JM, Park AE, Kim MH. HOXC9 Induces Phenotypic Switching between Proliferation and Invasion in Breast Cancer Cells. J Cancer 2016; 7: 768-73.
[27]
Mao L, Ding J, Zha Y, et al. HOXC9 links cell-cycle exit and neuronal differentiation and is a prognostic marker in neuroblastoma. Cancer Res 2011; 71: 4314-24.
[28]
Jin J, Arias EE, Chen J, Harper JW, Walter JC. A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1. Mol Cell 2006; 23: 709-21.
[29]
Scott J, Kuhn P, Anderson AR. Unifying metastasis--integrating intravasation, circulation and end-organ colonization. Nat Rev Cancer 2012; 12: 445-6.
[30]
Chen LT, Oh DY, Ryu MH, et al. Anti-angiogenic Therapy in Patients with Advanced Gastric and Gastroesophageal Junction Cancer: A Systematic Review. Cancer Res Treat 2017; 49: 851-68.
[31]
Niu Y, Wu Y, Huang J, et al. Identification of reference genes for circulating microRNA analysis in colorectal cancer. Sci Rep 2016; 6: 35611.
[32]
Planque C, Choi YH, Guyetant S, Heuze-Vourc’h N, Briollais L, Courty Y. Alternative splicing variant of kallikrein-related peptidase 8 as an independent predictor of unfavorable prognosis in lung cancer. Clin Chem 2010; 56: 987-97.
[33]
Gopal G, Raja UM, Shirley S, Rajalekshmi KR, Rajkumar T. SOSTDC1 down-regulation of expression involves CpG methylation and is a potential prognostic marker in gastric cancer. Cancer Genet 2013; 206: 174-82.
[34]
Liang W, Guan H, He X, et al. Down-regulation of SOSTDC1 promotes thyroid cancer cell proliferation via regulating cyclin A2 and cyclin E2. Oncotarget 2015; 6: 31780-91.
[35]
Tzeng ST, Tsai MH, Chen CL, et al. NDST4 is a novel candidate tumor suppressor gene at chromosome 4q26 and its genetic loss predicts adverse prognosis in colorectal cancer. PLoS One 2016; 8: e67040.